Long-term adverse outcomes persist after respiratory syncytial virus (RSV)-associated acute respiratory illness, ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. Susan Green developed a stubborn ...

Clinicians underutilize RSV testing in adults with respiratory or cardiac exacerbations, potentially obscuring the true burden of disease.

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization ...

Estimated vaccine effectiveness was significantly lower among immunocompromised than immunocompetent adults and for those with cardiovascular disease versus those without. HealthDay News — The ...

Providing year-round access to RSV immunization would minimize the risk of large seasonal outbreaks across the nation, including in both urban and rural areas. That's according to a new study, ...

A new letter signed by officials at the UKHSA and NHS England has been published by the Government ...

The Maryland Department of Health unveiled the Maryland Combined Respiratory Illness Data Dashboard on October 27, 2025, consolidating trends for COVID-19, influenza and respiratory syncytial virus to ...

Estimated vaccine effectiveness was significantly lower for immunocompromised adults and those with CVD. HealthDay News — The respiratory syncytial virus (RSV) vaccine reduces RSV-associated ...

Estimated vaccine effectiveness was significantly lower for immunocompromised adults and those with CVD. (HealthDay News) — The respiratory syncytial virus (RSV) vaccine reduces RSV-associated ...